Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × elotuzumab × 1 year × Clear all

Phase

Phase 2 8 Phase 3 5 Phase 1/2 4 Phase EARLY_PHASE1 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Magnetic Resonance Spectroscopy 21 Specimen Handling 15 Radiotherapy 15 pembrolizumab 13 Nivolumab 12 Cyclophosphamide 10 Biopsy 9 Fluorodeoxyglucose F18 8 X-Rays 7 fludarabine 6 Temozolomide 6 Radiation 6 Etoposide 6 Dexamethasone 6 Bevacizumab 6 venetoclax 5 Standard of Care 5 Metformin 5 Ipilimumab 5 Immune Checkpoint Inhibitors 5 Doxorubicin 5 olaparib 4 gallium 68 PSMA-11 4 fluciclovine F-18 4 durvalumab 4 abemaciclib 4 Rituximab 4 Prednisone 4 Paclitaxel 4 Methotrexate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05560399 2026-01-02

CC-220

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Active not recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡